Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, et al., Editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, 4th Edition. WHO; 2008.Google Scholar

Vose, J, Armitage, J, Weisenburger, D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26(25):4124−30.Google Scholar

Foss, FM, Zinzani, PL, Vose, JM, Gascoyne, RD, Rosen, ST, Tobinai, K. Peripheral T-cell lymphoma. Blood 2011;117(25):6756−67.CrossRefGoogle ScholarPubMed

Gisselbrecht, C, Gaulard, P, Lepage, E, Coiffier, B, Briere, J, Haioun, C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 1998;92(1):76–82.Google Scholar

Falini, B, Pileri, S, Zinzani, PL, Carbone, A, Zagonel, V, Wolf-Peeters, C, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999;93(8):2697–706.Google Scholar

Savage, KJ, Harris, NL, Vose, JM, Ullrich, F, Jaffe, ES, Connors, JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111(12):5496−504.CrossRefGoogle Scholar

Sibon, D, Fournier, M, Briere, J, Lamant, L, Haioun, C, Coiffier, B, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol 2012;30(32):3939–46.Google Scholar

Suzuki, R, Kagami, Y, Takeuchi, K, Kami, M, Okamoto, M, Ichinohasama, R, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 2000;96(9):2993–3000.Google Scholar

Pedersen, MB, Hamilton-Dutoit, SJ, Bendix, K, Moller, MB, Norgaard, P, Johansen, P, et al. Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry. Hematol Oncol 2015;33(4):120−8.Google Scholar

Ellin, F, Landstrom, J, Jerkeman, M, Relander, T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 2014;124(10):1570–7.Google Scholar

Parrilla Castellar, ER, Jaffe, ES, Said, JW, Swerdlow, SH, Ketterling, RP, Knudson, RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 2014;124(9):1473–80.CrossRefGoogle ScholarPubMed

Feldman, AL, Dogan, A, Smith, DI, Law, ME, Ansell, SM, Johnson, SH, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 2011;117(3):915−9.CrossRefGoogle Scholar

Abouyabis, AN, Shenoy, PJ, Sinha, R, Flowers, CR, Lechowicz, MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol 2011;2011:623924. doi: 10.5402/2011/623924. Epub;%2011 Jun 16.:623924.Google Scholar

Schmitz, N, Trumper, L, Ziepert, M, Nickelsen, M, Ho, AD, Metzner, B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116(18):3418−25.Google Scholar

Karakas, T, Bergmann, L, Stutte, HJ, Jager, E, Knuth, A, Weidmann, E, et al. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leuk Lymphoma 1996;24(1–2):121–9.CrossRefGoogle ScholarPubMed

Escalon, MP, Liu, NS, Yang, Y, Hess, M, Walker, PL, Smith, TL, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005;103(10):2091–8.CrossRefGoogle Scholar

Chihara, D, Pro, B, Loghavi, S, Miranda, RN, Medeiros, LJ, Fanale, MA, et al. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015;171(4):509−16.Google Scholar

Sung, HJ, Kim, SJ, Seo, HY, Sul, HR, Choi, JG, Choi, IK, et al. Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. Br J Haematol 2006;134(1):45–53.Google Scholar

Zinzani, PL, Venturini, F, Stefoni, V, Fina, M, Pellegrini, C, Derenzini, E, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010;21(4):860−3.Google Scholar

Zinzani, PL, Baliva, G, Magagnoli, M, Bendandi, M, Modugno, G, Gherlinzoni, F, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000;18(13):2603–6.Google Scholar

Kim, JG, Sohn, SK, Chae, YS, Kim, DH, Baek, JH, Lee, KB, et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 2006;58(1):35–9.Google Scholar

Mahadevan, D, Unger, JM, Spier, CM, Persky, DO, Young, F, LeBlanc, M, et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 2013;119(2):371–9.CrossRefGoogle Scholar

Kwong, YL, Kim, WS, Lim, ST, Kim, SJ, Tang, T, Tse, E, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012;120(15):2973–80.Google Scholar

Jaccard, A, Gachard, N, Marin, B, Rogez, S, Audrain, M, Suarez, F, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011;117(6):1834–9.CrossRefGoogle ScholarPubMed

Kim, WS, Song, SY, Ahn, YC, Ko, YH, Baek, CH, Kim, DY, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001;12(3):349–52.CrossRefGoogle ScholarPubMed

Rodriguez, J, Conde, E, Gutierrez, A, Arranz, R, Leon, A, Marin, J, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007;79(1):32–8.Google Scholar

Reimer, P, Rudiger, T, Geissinger, E, Weissinger, F, Nerl, C, Schmitz, N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009;27(1):106–13.Google Scholar

d’Amore, F, Relander, T, Lauritzsen, GF, Jantunen, E, Hagberg, H, Anderson, H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012;30(25):3093–9.Google Scholar

Corradini, P, Tarella, C, Zallio, F, Dodero, A, Zanni, M, Valagussa, P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20(9):1533–8.Google Scholar

Kyriakou, C, Canals, C, Goldstone, A, Caballero, D, Metzner, B, Kobbe, G, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26(2):218–24.Google Scholar

Schetelig, J, Fetscher, S, Reichle, A, Berdel, WE, Beguin, Y, Brunet, S, et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003;88(11):1272–8.Google Scholar

Rodriguez, J, Conde, E, Gutierrez, A, Arranz, R, Gandarillas, M, Leon, A, et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007;78(4):290–6.Google Scholar

Jantunen, E, Juvonen, E, Wiklund, T, Putkonen, M, Nousiainen, T. High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma. Leuk Lymphoma 2003;44(12):2163–4.CrossRefGoogle ScholarPubMed

Jantunen, E, Boumendil, A, Finel, H, Luan, JJ, Johnson, P, Rambaldi, A, et al. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. Blood 2013;121(13):2529–32.Google Scholar

Au, WY, Lie, AK, Liang, R, Kwong, YL, Yau, CC, Cheung, MM, et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 2003;14(11):1673–6.Google Scholar

Deconinck, E, Lamy, T, Foussard, C, Gaillard, F, Delwail, V, Colombat, P, et al. Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 2000;109(4):736−42.Google Scholar

Jagasia, M, Morgan, D, Goodman, S, Hamilton, K, Kinney, M, Shyr, Y, et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 2004;45(11):2261–7.Google Scholar

Rodriguez, J, Conde, E, Gutierrez, A, Arranz, R, Leon, A, Marin, J, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007;79(1):32–8.Google Scholar

Mercadal, S, Briones, J, Xicoy, B, Pedro, C, Escoda, L, Estany, C, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008;19(5):958–63.Google Scholar

Sieniawski, M, Angamuthu, N, Boyd, K, Chasty, R, Davies, J, Forsyth, P, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010;115(18):3664–70.CrossRefGoogle ScholarPubMed

Philip, T, Guglielmi, C, Hagenbeek, A, Somers, R, Van der Lelie, H, Bron, D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995;333(23):1540–5.Google Scholar

Fanin, R, Ruiz de Elvira, MC, Sperotto, A, Baccarani, M, Goldstone, A. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999;23(5):437−42.Google Scholar

Zamkoff, KW, Matulis, MD, Mehta, AC, Beaty, MW, Hutchison, RE, Gentile, TC. High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplant 2004;33(6):635–8.Google Scholar

Kewalramani, T, Zelenetz, AD, Teruya-Feldstein, J, Hamlin, P, Yahalom, J, Horwitz, S, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006;134(2):202–7.CrossRefGoogle ScholarPubMed

Kim, MK, Kim, S, Lee, SS, Sym, SJ, Lee, DH, Jang, S, et al. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol 2007;86(6):435−42.Google Scholar

Rodriguez, J, Caballero, MD, Gutierrez, A, Gandarillas, M, Sierra, J, Lopez-Guillermo, A, et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 2003;88(12):1372–7.Google Scholar

Song, KW, Mollee, P, Keating, A, Crump, M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003;120(6):978−85.Google Scholar

Jantunen, E, Itala, M, Juvonen, E, Leppa, S, Keskinen, L, Vasala, K, et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin’s lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006;37(4):367–72.Google Scholar

Kwong, YL, Anderson, BO, Advani, R, Kim, WS, Levine, AM, Lim, ST. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10(11):1093−101.Google Scholar

Loirat, M, Chevallier, P, Leux, C, Moreau, A, Bossard, C, Guillaume, T, et al. Upfront allogeneic-stem cell transplantation for patients with non-localized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol 2015;26(2):386−92.CrossRefGoogle Scholar

Corradini, P, Dodero, A, Zallio, F, Caracciolo, D, Casini, M, Bregni, M, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004;22(11):2172–6.Google Scholar

Dodero, A, Spina, F, Narni, F, Patriarca, F, Cavattoni, I, Benedetti, F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012;26(3):520–6.Google Scholar

Kim, SW, Tanimoto, TE, Hirabayashi, N, Goto, S, Kami, M, Yoshioka, S, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 2006;108(1):382–9.Google ScholarPubMed

Le, GS, Milpied, N, Buzyn, A, De Latour, RP, Vernant, JP, Mohty, M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008;26(14):2264–71.Google Scholar

Smith, SM, Burns, LJ, van BK, Lerademacher, J, He, W, Fenske, TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 2013;31(25):3100–9.Google Scholar

Corradini, P, Vitolo, U, Rambaldi, A, Miceli, R, Patriarca, F, Gallamini, A, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 2014;28(9):1885−91.Google Scholar

Voss, MH, Lunning, MA, Maragulia, JC, Papadopoulos, EB, Goldberg, J, Zelenetz, AD, et al. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk 2013;13(1):8−14.Google Scholar

Bazarbachi, A, Cwynarski, K, Boumendil, A, Finel, H, Fields, P, Raj, K, et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transplant 2014;49(10):1266–8.Google Scholar

Utsunomiya, A, Miyazaki, Y, Takatsuka, Y, Hanada, S, Uozumi, K, Yashiki, S, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;27(1):15–20.Google Scholar

Tsukasaki, K, Maeda, T, Arimura, K, Taguchi, J, Fukushima, T, Miyazaki, Y, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant 1999;23(1):87–9.Google Scholar

Woessmann, W, Peters, C, Lenhard, M, Burkhardt, B, Sykora, KW, Dilloo, D, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents–a Berlin-Frankfurt-Munster group report. Br J Haematol 2006;133(2):176–82.Google Scholar

Wulf, GG, Hasenkamp, J, Jung, W, Chapuy, B, Truemper, L, Glass, B. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin’s lymphoma. Bone Marrow Transplant 2005;36(3):271–3.CrossRefGoogle ScholarPubMed

Jacobsen, ED, Kim, HT, Ho, VT, Cutler, CS, Koreth, J, Fisher, DC, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 2011;22(7):1608−13.Google Scholar

Feyler, S, Prince, HM, Pearce, R, Towlson, K, Nivison-Smith, I, Schey, S, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007;40(5):443–50.Google Scholar

Corradini, P, Dodero, A, Farina, L, Fanin, R, Patriarca, F, Miceli, R, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pretransplant disease status and histotype heavily influence outcome. Leukemia 2007;21(11):2316−23.Google Scholar

Corradini, P, Vitolo, U, Rambaldi, A, Miceli, R, Patriarca, F, Gallamini, A, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 2014;28(9):1885–91.Google Scholar

Rodriguez, J, Conde, E, Gutierrez, A, Arranz, R, Leon, A, Marin, J, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007;18(4):652–7.Google Scholar

Kyriakou, C, Canals, C, Finke, J, Kobbe, G, Harousseau, JL, Kolb, HJ, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009;27(24):3951–8.Google Scholar

Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, et al., Editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, 4th Edition. WHO; 2008.Google Scholar

Vose, J, Armitage, J, Weisenburger, D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26(25):4124−30.Google Scholar

Foss, FM, Zinzani, PL, Vose, JM, Gascoyne, RD, Rosen, ST, Tobinai, K. Peripheral T-cell lymphoma. Blood 2011;117(25):6756−67.CrossRefGoogle ScholarPubMed

Gisselbrecht, C, Gaulard, P, Lepage, E, Coiffier, B, Briere, J, Haioun, C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 1998;92(1):76–82.Google Scholar

Falini, B, Pileri, S, Zinzani, PL, Carbone, A, Zagonel, V, Wolf-Peeters, C, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999;93(8):2697–706.Google Scholar

Savage, KJ, Harris, NL, Vose, JM, Ullrich, F, Jaffe, ES, Connors, JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111(12):5496−504.CrossRefGoogle Scholar

Sibon, D, Fournier, M, Briere, J, Lamant, L, Haioun, C, Coiffier, B, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol 2012;30(32):3939–46.Google Scholar

Suzuki, R, Kagami, Y, Takeuchi, K, Kami, M, Okamoto, M, Ichinohasama, R, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 2000;96(9):2993–3000.Google Scholar

Pedersen, MB, Hamilton-Dutoit, SJ, Bendix, K, Moller, MB, Norgaard, P, Johansen, P, et al. Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry. Hematol Oncol 2015;33(4):120−8.Google Scholar

Ellin, F, Landstrom, J, Jerkeman, M, Relander, T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 2014;124(10):1570–7.Google Scholar

Parrilla Castellar, ER, Jaffe, ES, Said, JW, Swerdlow, SH, Ketterling, RP, Knudson, RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 2014;124(9):1473–80.CrossRefGoogle ScholarPubMed

Feldman, AL, Dogan, A, Smith, DI, Law, ME, Ansell, SM, Johnson, SH, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 2011;117(3):915−9.CrossRefGoogle Scholar

Abouyabis, AN, Shenoy, PJ, Sinha, R, Flowers, CR, Lechowicz, MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol 2011;2011:623924. doi: 10.5402/2011/623924. Epub;%2011 Jun 16.:623924.Google Scholar

Schmitz, N, Trumper, L, Ziepert, M, Nickelsen, M, Ho, AD, Metzner, B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116(18):3418−25.Google Scholar

Karakas, T, Bergmann, L, Stutte, HJ, Jager, E, Knuth, A, Weidmann, E, et al. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leuk Lymphoma 1996;24(1–2):121–9.CrossRefGoogle ScholarPubMed

Escalon, MP, Liu, NS, Yang, Y, Hess, M, Walker, PL, Smith, TL, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005;103(10):2091–8.CrossRefGoogle Scholar

Chihara, D, Pro, B, Loghavi, S, Miranda, RN, Medeiros, LJ, Fanale, MA, et al. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015;171(4):509−16.Google Scholar

Sung, HJ, Kim, SJ, Seo, HY, Sul, HR, Choi, JG, Choi, IK, et al. Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. Br J Haematol 2006;134(1):45–53.Google Scholar

Zinzani, PL, Venturini, F, Stefoni, V, Fina, M, Pellegrini, C, Derenzini, E, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010;21(4):860−3.Google Scholar

Zinzani, PL, Baliva, G, Magagnoli, M, Bendandi, M, Modugno, G, Gherlinzoni, F, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000;18(13):2603–6.Google Scholar

Kim, JG, Sohn, SK, Chae, YS, Kim, DH, Baek, JH, Lee, KB, et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 2006;58(1):35–9.Google Scholar

Mahadevan, D, Unger, JM, Spier, CM, Persky, DO, Young, F, LeBlanc, M, et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 2013;119(2):371–9.CrossRefGoogle Scholar

Kwong, YL, Kim, WS, Lim, ST, Kim, SJ, Tang, T, Tse, E, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012;120(15):2973–80.Google Scholar

Jaccard, A, Gachard, N, Marin, B, Rogez, S, Audrain, M, Suarez, F, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011;117(6):1834–9.CrossRefGoogle ScholarPubMed

Kim, WS, Song, SY, Ahn, YC, Ko, YH, Baek, CH, Kim, DY, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001;12(3):349–52.CrossRefGoogle ScholarPubMed

Rodriguez, J, Conde, E, Gutierrez, A, Arranz, R, Leon, A, Marin, J, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007;79(1):32–8.Google Scholar

Reimer, P, Rudiger, T, Geissinger, E, Weissinger, F, Nerl, C, Schmitz, N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009;27(1):106–13.Google Scholar

d’Amore, F, Relander, T, Lauritzsen, GF, Jantunen, E, Hagberg, H, Anderson, H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012;30(25):3093–9.Google Scholar

Corradini, P, Tarella, C, Zallio, F, Dodero, A, Zanni, M, Valagussa, P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20(9):1533–8.Google Scholar

Kyriakou, C, Canals, C, Goldstone, A, Caballero, D, Metzner, B, Kobbe, G, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26(2):218–24.Google Scholar

Schetelig, J, Fetscher, S, Reichle, A, Berdel, WE, Beguin, Y, Brunet, S, et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003;88(11):1272–8.Google Scholar

Rodriguez, J, Conde, E, Gutierrez, A, Arranz, R, Gandarillas, M, Leon, A, et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007;78(4):290–6.Google Scholar

Jantunen, E, Juvonen, E, Wiklund, T, Putkonen, M, Nousiainen, T. High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma. Leuk Lymphoma 2003;44(12):2163–4.CrossRefGoogle ScholarPubMed

Jantunen, E, Boumendil, A, Finel, H, Luan, JJ, Johnson, P, Rambaldi, A, et al. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. Blood 2013;121(13):2529–32.Google Scholar

Au, WY, Lie, AK, Liang, R, Kwong, YL, Yau, CC, Cheung, MM, et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 2003;14(11):1673–6.Google Scholar

Deconinck, E, Lamy, T, Foussard, C, Gaillard, F, Delwail, V, Colombat, P, et al. Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 2000;109(4):736−42.Google Scholar

Jagasia, M, Morgan, D, Goodman, S, Hamilton, K, Kinney, M, Shyr, Y, et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 2004;45(11):2261–7.Google Scholar

Rodriguez, J, Conde, E, Gutierrez, A, Arranz, R, Leon, A, Marin, J, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007;79(1):32–8.Google Scholar

Mercadal, S, Briones, J, Xicoy, B, Pedro, C, Escoda, L, Estany, C, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008;19(5):958–63.Google Scholar

Sieniawski, M, Angamuthu, N, Boyd, K, Chasty, R, Davies, J, Forsyth, P, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010;115(18):3664–70.CrossRefGoogle ScholarPubMed

Philip, T, Guglielmi, C, Hagenbeek, A, Somers, R, Van der Lelie, H, Bron, D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995;333(23):1540–5.Google Scholar

Fanin, R, Ruiz de Elvira, MC, Sperotto, A, Baccarani, M, Goldstone, A. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999;23(5):437−42.Google Scholar

Zamkoff, KW, Matulis, MD, Mehta, AC, Beaty, MW, Hutchison, RE, Gentile, TC. High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplant 2004;33(6):635–8.Google Scholar

Kewalramani, T, Zelenetz, AD, Teruya-Feldstein, J, Hamlin, P, Yahalom, J, Horwitz, S, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006;134(2):202–7.CrossRefGoogle ScholarPubMed

Kim, MK, Kim, S, Lee, SS, Sym, SJ, Lee, DH, Jang, S, et al. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol 2007;86(6):435−42.Google Scholar

Rodriguez, J, Caballero, MD, Gutierrez, A, Gandarillas, M, Sierra, J, Lopez-Guillermo, A, et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 2003;88(12):1372–7.Google Scholar

Song, KW, Mollee, P, Keating, A, Crump, M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003;120(6):978−85.Google Scholar

Jantunen, E, Itala, M, Juvonen, E, Leppa, S, Keskinen, L, Vasala, K, et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin’s lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006;37(4):367–72.Google Scholar

Kwong, YL, Anderson, BO, Advani, R, Kim, WS, Levine, AM, Lim, ST. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10(11):1093−101.Google Scholar

Loirat, M, Chevallier, P, Leux, C, Moreau, A, Bossard, C, Guillaume, T, et al. Upfront allogeneic-stem cell transplantation for patients with non-localized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol 2015;26(2):386−92.CrossRefGoogle Scholar

Corradini, P, Dodero, A, Zallio, F, Caracciolo, D, Casini, M, Bregni, M, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004;22(11):2172–6.Google Scholar

Dodero, A, Spina, F, Narni, F, Patriarca, F, Cavattoni, I, Benedetti, F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012;26(3):520–6.Google Scholar

Kim, SW, Tanimoto, TE, Hirabayashi, N, Goto, S, Kami, M, Yoshioka, S, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 2006;108(1):382–9.Google ScholarPubMed

Le, GS, Milpied, N, Buzyn, A, De Latour, RP, Vernant, JP, Mohty, M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008;26(14):2264–71.Google Scholar

Smith, SM, Burns, LJ, van BK, Lerademacher, J, He, W, Fenske, TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 2013;31(25):3100–9.Google Scholar

Corradini, P, Vitolo, U, Rambaldi, A, Miceli, R, Patriarca, F, Gallamini, A, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 2014;28(9):1885−91.Google Scholar

Voss, MH, Lunning, MA, Maragulia, JC, Papadopoulos, EB, Goldberg, J, Zelenetz, AD, et al. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk 2013;13(1):8−14.Google Scholar

Bazarbachi, A, Cwynarski, K, Boumendil, A, Finel, H, Fields, P, Raj, K, et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transplant 2014;49(10):1266–8.Google Scholar

Utsunomiya, A, Miyazaki, Y, Takatsuka, Y, Hanada, S, Uozumi, K, Yashiki, S, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;27(1):15–20.Google Scholar

Tsukasaki, K, Maeda, T, Arimura, K, Taguchi, J, Fukushima, T, Miyazaki, Y, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant 1999;23(1):87–9.Google Scholar

Woessmann, W, Peters, C, Lenhard, M, Burkhardt, B, Sykora, KW, Dilloo, D, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents–a Berlin-Frankfurt-Munster group report. Br J Haematol 2006;133(2):176–82.Google Scholar

Wulf, GG, Hasenkamp, J, Jung, W, Chapuy, B, Truemper, L, Glass, B. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin’s lymphoma. Bone Marrow Transplant 2005;36(3):271–3.CrossRefGoogle ScholarPubMed

Jacobsen, ED, Kim, HT, Ho, VT, Cutler, CS, Koreth, J, Fisher, DC, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 2011;22(7):1608−13.Google Scholar

Feyler, S, Prince, HM, Pearce, R, Towlson, K, Nivison-Smith, I, Schey, S, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007;40(5):443–50.Google Scholar

Corradini, P, Dodero, A, Farina, L, Fanin, R, Patriarca, F, Miceli, R, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pretransplant disease status and histotype heavily influence outcome. Leukemia 2007;21(11):2316−23.Google Scholar

Corradini, P, Vitolo, U, Rambaldi, A, Miceli, R, Patriarca, F, Gallamini, A, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 2014;28(9):1885–91.Google Scholar

Rodriguez, J, Conde, E, Gutierrez, A, Arranz, R, Leon, A, Marin, J, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007;18(4):652–7.Google Scholar

Kyriakou, C, Canals, C, Finke, J, Kobbe, G, Harousseau, JL, Kolb, HJ, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009;27(24):3951–8.Google Scholar

Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, et al., Editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, 4th Edition. WHO; 2008.Google Scholar

Vose, J, Armitage, J, Weisenburger, D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26(25):4124−30.Google Scholar

Foss, FM, Zinzani, PL, Vose, JM, Gascoyne, RD, Rosen, ST, Tobinai, K. Peripheral T-cell lymphoma. Blood 2011;117(25):6756−67.CrossRefGoogle ScholarPubMed

Gisselbrecht, C, Gaulard, P, Lepage, E, Coiffier, B, Briere, J, Haioun, C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 1998;92(1):76–82.Google Scholar

Falini, B, Pileri, S, Zinzani, PL, Carbone, A, Zagonel, V, Wolf-Peeters, C, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999;93(8):2697–706.Google Scholar

Savage, KJ, Harris, NL, Vose, JM, Ullrich, F, Jaffe, ES, Connors, JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111(12):5496−504.CrossRefGoogle Scholar

Sibon, D, Fournier, M, Briere, J, Lamant, L, Haioun, C, Coiffier, B, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol 2012;30(32):3939–46.Google Scholar

Suzuki, R, Kagami, Y, Takeuchi, K, Kami, M, Okamoto, M, Ichinohasama, R, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 2000;96(9):2993–3000.Google Scholar

Pedersen, MB, Hamilton-Dutoit, SJ, Bendix, K, Moller, MB, Norgaard, P, Johansen, P, et al. Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry. Hematol Oncol 2015;33(4):120−8.Google Scholar

Ellin, F, Landstrom, J, Jerkeman, M, Relander, T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 2014;124(10):1570–7.Google Scholar

Parrilla Castellar, ER, Jaffe, ES, Said, JW, Swerdlow, SH, Ketterling, RP, Knudson, RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 2014;124(9):1473–80.CrossRefGoogle ScholarPubMed

Feldman, AL, Dogan, A, Smith, DI, Law, ME, Ansell, SM, Johnson, SH, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 2011;117(3):915−9.CrossRefGoogle Scholar

Abouyabis, AN, Shenoy, PJ, Sinha, R, Flowers, CR, Lechowicz, MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol 2011;2011:623924. doi: 10.5402/2011/623924. Epub;%2011 Jun 16.:623924.Google Scholar

Schmitz, N, Trumper, L, Ziepert, M, Nickelsen, M, Ho, AD, Metzner, B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116(18):3418−25.Google Scholar

Karakas, T, Bergmann, L, Stutte, HJ, Jager, E, Knuth, A, Weidmann, E, et al. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leuk Lymphoma 1996;24(1–2):121–9.CrossRefGoogle ScholarPubMed

Escalon, MP, Liu, NS, Yang, Y, Hess, M, Walker, PL, Smith, TL, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005;103(10):2091–8.CrossRefGoogle Scholar

Chihara, D, Pro, B, Loghavi, S, Miranda, RN, Medeiros, LJ, Fanale, MA, et al. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015;171(4):509−16.Google Scholar

Sung, HJ, Kim, SJ, Seo, HY, Sul, HR, Choi, JG, Choi, IK, et al. Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study. Br J Haematol 2006;134(1):45–53.Google Scholar

Zinzani, PL, Venturini, F, Stefoni, V, Fina, M, Pellegrini, C, Derenzini, E, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010;21(4):860−3.Google Scholar

Zinzani, PL, Baliva, G, Magagnoli, M, Bendandi, M, Modugno, G, Gherlinzoni, F, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000;18(13):2603–6.Google Scholar

Kim, JG, Sohn, SK, Chae, YS, Kim, DH, Baek, JH, Lee, KB, et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 2006;58(1):35–9.Google Scholar

Mahadevan, D, Unger, JM, Spier, CM, Persky, DO, Young, F, LeBlanc, M, et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 2013;119(2):371–9.CrossRefGoogle Scholar

Kwong, YL, Kim, WS, Lim, ST, Kim, SJ, Tang, T, Tse, E, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012;120(15):2973–80.Google Scholar

Jaccard, A, Gachard, N, Marin, B, Rogez, S, Audrain, M, Suarez, F, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011;117(6):1834–9.CrossRefGoogle ScholarPubMed

Kim, WS, Song, SY, Ahn, YC, Ko, YH, Baek, CH, Kim, DY, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001;12(3):349–52.CrossRefGoogle ScholarPubMed

Rodriguez, J, Conde, E, Gutierrez, A, Arranz, R, Leon, A, Marin, J, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007;79(1):32–8.Google Scholar

Reimer, P, Rudiger, T, Geissinger, E, Weissinger, F, Nerl, C, Schmitz, N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009;27(1):106–13.Google Scholar

d’Amore, F, Relander, T, Lauritzsen, GF, Jantunen, E, Hagberg, H, Anderson, H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012;30(25):3093–9.Google Scholar

Corradini, P, Tarella, C, Zallio, F, Dodero, A, Zanni, M, Valagussa, P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20(9):1533–8.Google Scholar

Kyriakou, C, Canals, C, Goldstone, A, Caballero, D, Metzner, B, Kobbe, G, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26(2):218–24.Google Scholar

Schetelig, J, Fetscher, S, Reichle, A, Berdel, WE, Beguin, Y, Brunet, S, et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003;88(11):1272–8.Google Scholar

Rodriguez, J, Conde, E, Gutierrez, A, Arranz, R, Gandarillas, M, Leon, A, et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007;78(4):290–6.Google Scholar

Jantunen, E, Juvonen, E, Wiklund, T, Putkonen, M, Nousiainen, T. High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma. Leuk Lymphoma 2003;44(12):2163–4.CrossRefGoogle ScholarPubMed

Jantunen, E, Boumendil, A, Finel, H, Luan, JJ, Johnson, P, Rambaldi, A, et al. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. Blood 2013;121(13):2529–32.Google Scholar

Au, WY, Lie, AK, Liang, R, Kwong, YL, Yau, CC, Cheung, MM, et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 2003;14(11):1673–6.Google Scholar

Deconinck, E, Lamy, T, Foussard, C, Gaillard, F, Delwail, V, Colombat, P, et al. Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 2000;109(4):736−42.Google Scholar

Jagasia, M, Morgan, D, Goodman, S, Hamilton, K, Kinney, M, Shyr, Y, et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 2004;45(11):2261–7.Google Scholar

Rodriguez, J, Conde, E, Gutierrez, A, Arranz, R, Leon, A, Marin, J, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007;79(1):32–8.Google Scholar

Mercadal, S, Briones, J, Xicoy, B, Pedro, C, Escoda, L, Estany, C, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008;19(5):958–63.Google Scholar

Sieniawski, M, Angamuthu, N, Boyd, K, Chasty, R, Davies, J, Forsyth, P, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010;115(18):3664–70.CrossRefGoogle ScholarPubMed

Philip, T, Guglielmi, C, Hagenbeek, A, Somers, R, Van der Lelie, H, Bron, D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995;333(23):1540–5.Google Scholar

Fanin, R, Ruiz de Elvira, MC, Sperotto, A, Baccarani, M, Goldstone, A. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999;23(5):437−42.Google Scholar

Zamkoff, KW, Matulis, MD, Mehta, AC, Beaty, MW, Hutchison, RE, Gentile, TC. High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplant 2004;33(6):635–8.Google Scholar

Kewalramani, T, Zelenetz, AD, Teruya-Feldstein, J, Hamlin, P, Yahalom, J, Horwitz, S, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006;134(2):202–7.CrossRefGoogle ScholarPubMed

Kim, MK, Kim, S, Lee, SS, Sym, SJ, Lee, DH, Jang, S, et al. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol 2007;86(6):435−42.Google Scholar

Rodriguez, J, Caballero, MD, Gutierrez, A, Gandarillas, M, Sierra, J, Lopez-Guillermo, A, et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 2003;88(12):1372–7.Google Scholar

Song, KW, Mollee, P, Keating, A, Crump, M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003;120(6):978−85.Google Scholar

Jantunen, E, Itala, M, Juvonen, E, Leppa, S, Keskinen, L, Vasala, K, et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin’s lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006;37(4):367–72.Google Scholar

Kwong, YL, Anderson, BO, Advani, R, Kim, WS, Levine, AM, Lim, ST. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10(11):1093−101.Google Scholar

Loirat, M, Chevallier, P, Leux, C, Moreau, A, Bossard, C, Guillaume, T, et al. Upfront allogeneic-stem cell transplantation for patients with non-localized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol 2015;26(2):386−92.CrossRefGoogle Scholar

Corradini, P, Dodero, A, Zallio, F, Caracciolo, D, Casini, M, Bregni, M, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004;22(11):2172–6.Google Scholar

Dodero, A, Spina, F, Narni, F, Patriarca, F, Cavattoni, I, Benedetti, F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012;26(3):520–6.Google Scholar

Kim, SW, Tanimoto, TE, Hirabayashi, N, Goto, S, Kami, M, Yoshioka, S, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 2006;108(1):382–9.Google ScholarPubMed

Le, GS, Milpied, N, Buzyn, A, De Latour, RP, Vernant, JP, Mohty, M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008;26(14):2264–71.Google Scholar

Smith, SM, Burns, LJ, van BK, Lerademacher, J, He, W, Fenske, TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 2013;31(25):3100–9.Google Scholar

Corradini, P, Vitolo, U, Rambaldi, A, Miceli, R, Patriarca, F, Gallamini, A, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 2014;28(9):1885−91.Google Scholar

Voss, MH, Lunning, MA, Maragulia, JC, Papadopoulos, EB, Goldberg, J, Zelenetz, AD, et al. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk 2013;13(1):8−14.Google Scholar

Bazarbachi, A, Cwynarski, K, Boumendil, A, Finel, H, Fields, P, Raj, K, et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transplant 2014;49(10):1266–8.Google Scholar

Utsunomiya, A, Miyazaki, Y, Takatsuka, Y, Hanada, S, Uozumi, K, Yashiki, S, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;27(1):15–20.Google Scholar

Tsukasaki, K, Maeda, T, Arimura, K, Taguchi, J, Fukushima, T, Miyazaki, Y, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant 1999;23(1):87–9.Google Scholar

Woessmann, W, Peters, C, Lenhard, M, Burkhardt, B, Sykora, KW, Dilloo, D, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents–a Berlin-Frankfurt-Munster group report. Br J Haematol 2006;133(2):176–82.Google Scholar

Wulf, GG, Hasenkamp, J, Jung, W, Chapuy, B, Truemper, L, Glass, B. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin’s lymphoma. Bone Marrow Transplant 2005;36(3):271–3.CrossRefGoogle ScholarPubMed

Jacobsen, ED, Kim, HT, Ho, VT, Cutler, CS, Koreth, J, Fisher, DC, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 2011;22(7):1608−13.Google Scholar

Feyler, S, Prince, HM, Pearce, R, Towlson, K, Nivison-Smith, I, Schey, S, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007;40(5):443–50.Google Scholar

Corradini, P, Dodero, A, Farina, L, Fanin, R, Patriarca, F, Miceli, R, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pretransplant disease status and histotype heavily influence outcome. Leukemia 2007;21(11):2316−23.Google Scholar

Corradini, P, Vitolo, U, Rambaldi, A, Miceli, R, Patriarca, F, Gallamini, A, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 2014;28(9):1885–91.Google Scholar

Rodriguez, J, Conde, E, Gutierrez, A, Arranz, R, Leon, A, Marin, J, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007;18(4):652–7.Google Scholar

Kyriakou, C, Canals, C, Finke, J, Kobbe, G, Harousseau, JL, Kolb, HJ, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009;27(24):3951–8.Google Scholar